S-腺苷甲硫胺酸 SAMe × 憂鬱症

結論:證據支持但有警示

SAMe for depression has a genuine but limited evidence base.

C 🟠 C 薄弱證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

SAMe for depression has a genuine but limited evidence base. The largest 2024 meta-analysis (23 trials, n=2183) found SAMe monotherapy significantly superior to placebo (SMD -0.58), and this is corroborated by Examine's grade B (11 studies, 1558 participants, small improvement). However, the same meta-analysis found no benefit as an adjunct or head-to-head versus antidepressants, a second 2024 meta-analysis found no significant difference in any comparison, the rigorous 2018 adjunctive RCT (n=107, 800 mg/day) was negative (p=0.51), and the 2016 Cochrane review rated the overall evidence very-low to low quality. Trials are heterogeneous (I2 up to 68%), dosing varies enormously (200-3200 mg/day), and many are old and small with unclear risk of bias. The APA guideline describes only modest evidence and NCCIH concludes research has not conclusively shown benefit, so a grade higher than B is not warranted; a grade B with explicit caveats is the honest, evidence-proportionate call.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.49
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
74%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧/統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L5 臨床機構權威立場
0.43
L2 PubMed原始文獻
0.45
L3 機轉生理合理性
0.45
L11 AI 複核獨立判讀
0.65
L1 Examine國際基準
0.70
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.491
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta-analysis
PMID: 38423354 2024 統合分析 n = 2,183
結論:Across 23 trials, SAMe was significantly superior to placebo as monotherapy (SMD -0.58, 95% CI -0.93 to -0.23, I2 68%). SAMe did not differ significantly from antidepressants (SMD 0.06, 95% CI -0.06 to 0.18) nor from placebo when added to ongoing antidepressants (SMD -0.22, 95% CI -0.63 to 0.19). Subgroup analysis: intramuscular (SMD -0.92) and oral (SMD -0.66) routes effective, intravenous route not (SMD -0.16). No significant difference in dropout rates.
效應量:SMD vs placebo -0.58 (monotherapy); vs antidepressant 0.06 (NS); as adjunct -0.22 (NS)
前往 PubMed
S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis
PMID: 38199136 2024 統合分析 n = 1,522
結論:Across 14 trials (1522 subjects), no significant difference in depression outcome was found between SAMe and the comparator across monotherapy vs placebo, SAMe vs imipramine/escitalopram, and adjunctive vs placebo comparisons. SAMe provided relief comparable to established antidepressants, but authors urge caution given limited trial number and highly variable dosing.
效應量:No significant difference vs comparators across analyses
前往 PubMed
S-adenosyl methionine (SAMe) for depression in adults (Cochrane Systematic Review)
PMID: 27727432 2016 Cochrane SR n = 934
結論:Across 8 RCTs (934 adults): no strong evidence of a difference between SAMe and placebo as monotherapy (very low quality evidence). SAMe equivalent to tricyclic antidepressants (imipramine) and to SSRI (escitalopram) with fewer adverse effects than imipramine (low quality). SAMe as add-on to SSRIs showed superiority over placebo (low quality). Authors concluded the absence of high-quality evidence precludes firm conclusions; large high-quality RCTs needed.
🟠 品質有限 政府資助 效應量:No significant difference vs placebo (monotherapy); equivalent to TCA/SSRI; favorable as SSRI add-on
前往 PubMed
Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial
PMID: 30115553 2018 RCT (double-blind) n = 107
結論:In 107 treatment non-remittent MDD outpatients, adjunctive SAMe 800 mg/day showed no significant between-group difference vs placebo (p=0.51). Response 54.3% SAMe vs 50.0% placebo; remission 43.5% vs 38.3%. No effect on any secondary outcome. Authors concluded 800 mg/day SAMe is not an effective adjunctive treatment in MDD.
效應量:No significant difference vs placebo (adjunctive)
前往 PubMed

L4a US FDA
謹慎
A lab-made form of SAMe is sold as a dietary supplement in the U.S., but SAMe has been sold as a prescription drug in parts of Europe for decades. 來源↗
L4b EU EFSA
未表態
— 本適應症無對應資料
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
從 1970 年代起,歐洲已廣泛使用 SAMe 來治療憂鬱症及其他生理狀況;1999 年美國則依《膳食補充劑健康與教育法》核准口服腸溶 SAMe 劑型,使消費者得於零售通路購買。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
謹慎
While research has shown that SAMe has a positive effect in treating depression, most studies weren't well designed and included a small number of people. However, SAMe appears to be safe and might be effective in treating depression and osteoarthritis. 來源↗
L5c Cleveland Clinic
中性
L5d Harvard Health
謹慎
L5e Specialty Society (condition-mapped)
謹慎

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

SAMe 在台灣 PTT/Dcard/Mobile01 幾乎沒有針對憂鬱症的原生第一人稱實測討論,訊號極低。可見資料以藥師部落格(微笑藥師網)、保健文章(營養新知、EVIS)、iHerb 代購與廠商商品頁(SAMe-X、Life Extension)為主,屬商業/衛教內容而非鄉民心得。藥師端反映民眾偶有諮詢,但社群並無實際使用憂鬱症的經驗共識。

💬社群實感

無共識(台灣社群針對憂鬱症的原生實測討論稀少,可見內容多為藥師/保健媒體衛教與代購開箱,非鄉民心得)

破解迷思 社群最常見的 4 個誤解
事實誤以為 SAMe 抗憂鬱已充分實證可取代抗憂鬱藥(2016 Cochrane 回顧認為證據仍不足,社群/藥師皆強調須就醫)
事實誤以為 SAMe 是台灣合法上架的保健食品(實際少見一般通路販售,多須 iHerb 或美國 Costco 代購)
事實把 SAMe 主打的『護肝』與『情緒』功效混為一談,誤以為吃了就能同時治憂鬱
事實誤以為劑量越高越好(高劑量易致噁心、腹瀉、失眠,少數人出現躁動)
🩹 社群通報的副作用
  • 噁心、腹瀉、排氣等腸胃不適(衛教來源,社群第一手回饋稀少)
  • 輕度失眠、頭暈、頭痛
  • 少數人服用後較為躁動/焦躁(藥師部落格提及,原因不明)
  • 與 SSRI 併用之血清素症候群風險(警語層級,非社群實測)
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • Nature Made SAM-e Complete 400mg(美國 Costco 代購最常被提及)
  • Life Extension SAMe(iHerb 代購,腸溶錠 200mg)
  • NOW Foods/Doctor's Best 等 iHerb 進口腸溶錠
  • SAMe-X 酵母發酵物(漢馨科技,台灣少數本地廠商品)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

NOW Foods, SAMe, 400 mg, 60 Tablets

代表來源 ↗
L10b · TFDA 法定身份 官方認定

S-腺苷甲硫氨酸據說對抑鬱、骨關節炎、膽汁淤積和肝功能異常的治療都有效;商品名稱包括思美泰/Transmetil。

來源 ↗

  • 心理治療(CBT/人際治療)
  • 抗憂鬱藥物(SSRI 等)
  • 規律運動
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v24 engine_version: v1.0 claim_id: CLM-COND-depression-INT-s-adenosylmethionine-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-depression-INT-s-adenosylmethionine-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "S-腺苷甲硫胺酸能改善憂鬱症",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}